| Literature DB >> 25552775 |
Sanne Jespersen1, Bo Langhoff Hønge1, Inés Oliveira1, Candida Medina2, David da Silva Té2, Faustino Gomes Correia2, Zacarias José da Silva3, Christian Erikstrup4, Lars Østergaard5, Alex Lund Laursen5, Christian Wejse6.
Abstract
PROBLEM: The introduction of antiretroviral therapy (ART) for HIV infection in sub-Saharan Africa has improved the quality of life of millions of people and reduced mortality. However, substantial problems with the infrastructure for ART delivery remain. APPROACH: Clinicians and researchers at an HIV clinic in Guinea-Bissau identified problems with the delivery of ART by establishing a clinical database and by collaborating with international researchers. LOCALEntities:
Mesh:
Substances:
Year: 2014 PMID: 25552775 PMCID: PMC4264391 DOI: 10.2471/BLT.14.135749
Source DB: PubMed Journal: Bull World Health Organ ISSN: 0042-9686 Impact factor: 9.408
Patients attending an HIV clinic, Guinea-Bissau, 2005–2013
| Characteristic | No. (%)a of patients ( |
|---|---|
| Female | 3590 (65) |
| Male | 1922 (35) |
| Missing data | 2 (0.04) |
| 36 (29–45) | |
| HIV-1 | 3697 (67) |
| HIV-2 | 954 (17) |
| HIV-1 and HIV-2 | 598 (11) |
| Missing data | 265 (5) |
| Yes | 3699 (67) |
| No | 1815 (33) |
| 197 (79–375) | |
| Yes | 3170 (57) |
| No | 2344 (43) |
ART: antiretroviral therapy; CD4: cluster of differentiation 4; HIV: human immunodeficiency virus; IQR: interquartile range.
a All values represent absolute numbers and percentages unless otherwise stated.
Problems with ART delivery at an HIV clinic, Guinea-Bissau, 2005–2013
| Problem | Effect | Solution |
|---|---|---|
| Patients with a high CD4+ T-lymphocyte count experienced Stevens–Johnson syndrome on switching from efavirenz to nevirapine after stocks of efavirenz ran out;8 development of drug resistance due to treatment interruptions | Improve stock management, increase investment in health-care infrastructure and capacity | |
| Patients lost to follow-up | Increase the focus on HIV infection at the hospital to give the disease a higher priority among policy-makers | |
| Patients not adequately treated | Identify risk factors for patients being lost to follow-up so that effort can be focused on the most vulnerable;9 introduce educational activities for patients to improve health literacy; telephone patients who are late for appointments; visit patients lost to follow-up at home | |
| Treatment failure and drug resistance | Identify risk factors for poor adherence;10 improve health literacy | |
| Inadequate validation of HIV rapid tests | Errors in discriminating between infection with HIV-1, HIV-2 and both HIV-1 and HIV-2 occurred with the SD Bioline HIV 1/2 3.0 rapid test (Standard Diagnostics Inc., Yongin, Republic of Korea);11 ineffective treatment for HIV-2 infection using non-nucleotide reverse transcriptase inhibitors; expensive treatment for HIV-1 infection using protease inhibitors | Use other rapid HIV diagnostic tests |
| Temporary unavailability of biochemical tests and CD4+ T-cell count measurements | Delayed initiation of ART; late diagnosis of treatment failure; adverse events not diagnosed | Increase awareness of possible treatment failure |
| No HIV-RNA monitoring | Late diagnosis of treatment failure; development of drug resistance | Increase the ability of the laboratory to perform HIV-RNA measurements |
| Insufficient tuberculosis screening | Tuberculosis not diagnosed, leading to no tuberculosis treatment and increased mortality; no detection of drug-resistant tuberculosis | Introduce a simple clinical tuberculosis score together with a rapid urine test for the disease; introduce tuberculosis culture and drug-resistance tests |
| Insufficient hepatitis screening | No hepatitis treatment due to low sensitivity of rapid tests for hepatitis B and C viruses12 | Increase awareness of the limitations of rapid tests |
ART: antiretroviral therapy; CD4: cluster of differentiation 4; HIV: human immunodeficiency virus; RNA: ribonucleic acid.